Corporate Updates

Alvogen gets US FDA nod to market antiviral drug

Views: 1.2K

US FDA has given a green signal to the marketing partner of Natco Pharma, Alvogen to market oseltamivir phosphate powder —an antiviral medication used for the treatment of influenza virus types A and B in the body — for oral suspension in the United States.

Natco Pharma said: “Alvogen has received final approval and is the first to market generic equivalent to oseltamivir phosphate, 6 mg/ml powder”.

The Chairman and CEO of Alvogen Robert Wessman, said: “The approval and launch of Alvogen’s oseltamivir phosphate powder for oral suspension is great news for the US patients, who will have access to a more affordable alternative.”  

According to IMS Midas data, the annual sales for Oseltamivir suspension amount to the US $312 million in the U.S. market.

Currently, 75 products of Alvogen are in development and pending for FDA approvals for the U.S. market.

Most Popular





Get Heard Portal


eHealth Event Report




About Us

eHEALTH, as an online and print platform, elegantly guides the healthcare stakeholders through the trajectory of healthcare that witnesses fascinating changes on a daily basis due to increased technological intervention and other structural changes to create a ‘community of practice’ of healthcare stakeholders.


Contact Us

Elets Technomedia Pvt. Ltd.
Stellar IT Park, Office No. 7A/7B, 5th Floor, Tower -2 Annexe Building, C-25, Sector 62 Noida, Uttar Pradesh - 201309, India

Copyright © 2018 Elets | All rights reserved

To Top